Selected research
Industry Research
Extended-release Medication Industry Research Report 2026
Market perspective
The global Extended-release Medication market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Extended-release Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Extended-release Medication market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Extended-release Medication market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Extended-release Medication include Shanghai Shyndec Pharmaceutical, Takeda, Sanofi, Zhuhai Rundu Pharmaceutical, Johnson & Johnson, Novartis, Pfizer, Bayer and AbbVie, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Extended-release Medication market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Extended-release Medication.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Extended-release Medication Market by Company
Shanghai Shyndec Pharmaceutical
Takeda
Sanofi
Zhuhai Rundu Pharmaceutical
Johnson & Johnson
Novartis
Pfizer
Bayer
AbbVie
AstraZeneca
Endo Pharmaceuticals
Collegium Pharmaceutical, Inc
China Res Double-Crane
Extended-release Medication Segment by Type
Original Medication
Generic Medication
Extended-release Medication Segment by Application
Hospital
Drugstore
Other
Extended-release Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Extended-release Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Extended-release Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Extended-release Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Extended-release Medication companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Medication
- Generic Medication
Applications
- Hospital
- Drugstore
- Other
Companies covered
- Shanghai Shyndec Pharmaceutical
- Takeda
- Sanofi
- Zhuhai Rundu Pharmaceutical
- Johnson & Johnson
- Novartis
- Pfizer
- Bayer
- AbbVie
- AstraZeneca
- Endo Pharmaceuticals
- Collegium Pharmaceutical, Inc
- China Res Double-Crane
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Extended-release Medication by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Original Medication
- 2.2.3 Generic Medication
- 2.3 Extended-release Medication by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Drugstore
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Extended-release Medication Breakdown Data by Type
- 3.1 Global Extended-release Medication Historic Market Size by Type (2021-2026)
- 3.2 Global Extended-release Medication Forecasted Market Size by Type (2027-2032)
4 Extended-release Medication Breakdown Data by Application
- 4.1 Global Extended-release Medication Historic Market Size by Application (2021-2026)
- 4.2 Global Extended-release Medication Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Extended-release Medication Market Perspective (2021-2032)
- 5.2 Global Extended-release Medication Growth Trends by Region
- 5.2.1 Global Extended-release Medication Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Extended-release Medication Historic Market Size by Region (2021-2026)
- 5.2.3 Extended-release Medication Forecasted Market Size by Region (2027-2032)
- 5.3 Extended-release Medication Market Dynamics
- 5.3.1 Extended-release Medication Industry Trends
- 5.3.2 Extended-release Medication Market Drivers
- 5.3.3 Extended-release Medication Market Challenges
- 5.3.4 Extended-release Medication Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Extended-release Medication Players by Revenue
- 6.1.1 Global Top Extended-release Medication Players by Revenue (2021-2026)
- 6.1.2 Global Extended-release Medication Revenue Market Share by Players (2021-2026)
- 6.2 Global Extended-release Medication Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Extended-release Medication Head Office and Area Served
- 6.4 Global Extended-release Medication Players, Product Type & Application
- 6.5 Global Extended-release Medication Manufacturers Established Date
- 6.6 Global Extended-release Medication Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Extended-release Medication Market Size (2021-2032)
- 7.2 North America Extended-release Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Extended-release Medication Market Size by Country (2021-2026)
- 7.4 North America Extended-release Medication Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Extended-release Medication Market Size (2021-2032)
- 8.2 Europe Extended-release Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Extended-release Medication Market Size by Country (2021-2026)
- 8.4 Europe Extended-release Medication Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Extended-release Medication Market Size (2021-2032)
- 9.2 Asia-Pacific Extended-release Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Extended-release Medication Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Extended-release Medication Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Extended-release Medication Market Size (2021-2032)
- 10.2 South America Extended-release Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Extended-release Medication Market Size by Country (2021-2026)
- 10.4 South America Extended-release Medication Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Extended-release Medication Market Size (2021-2032)
- 11.2 Middle East & Africa Extended-release Medication Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Extended-release Medication Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Extended-release Medication Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Shanghai Shyndec Pharmaceutical
- 12.1.1 Shanghai Shyndec Pharmaceutical Company Information
- 12.1.2 Shanghai Shyndec Pharmaceutical Business Overview
- 12.1.3 Shanghai Shyndec Pharmaceutical Revenue in Extended-release Medication Business (2021-2026)
- 12.1.4 Shanghai Shyndec Pharmaceutical Extended-release Medication Product Portfolio
- 12.1.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Extended-release Medication Business (2021-2026)
- 12.2.4 Takeda Extended-release Medication Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Extended-release Medication Business (2021-2026)
- 12.3.4 Sanofi Extended-release Medication Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Zhuhai Rundu Pharmaceutical
- 12.4.1 Zhuhai Rundu Pharmaceutical Company Information
- 12.4.2 Zhuhai Rundu Pharmaceutical Business Overview
- 12.4.3 Zhuhai Rundu Pharmaceutical Revenue in Extended-release Medication Business (2021-2026)
- 12.4.4 Zhuhai Rundu Pharmaceutical Extended-release Medication Product Portfolio
- 12.4.5 Zhuhai Rundu Pharmaceutical Recent Developments
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Information
- 12.5.2 Johnson & Johnson Business Overview
- 12.5.3 Johnson & Johnson Revenue in Extended-release Medication Business (2021-2026)
- 12.5.4 Johnson & Johnson Extended-release Medication Product Portfolio
- 12.5.5 Johnson & Johnson Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Extended-release Medication Business (2021-2026)
- 12.6.4 Novartis Extended-release Medication Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Extended-release Medication Business (2021-2026)
- 12.7.4 Pfizer Extended-release Medication Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Bayer
- 12.8.1 Bayer Company Information
- 12.8.2 Bayer Business Overview
- 12.8.3 Bayer Revenue in Extended-release Medication Business (2021-2026)
- 12.8.4 Bayer Extended-release Medication Product Portfolio
- 12.8.5 Bayer Recent Developments
- 12.9 AbbVie
- 12.9.1 AbbVie Company Information
- 12.9.2 AbbVie Business Overview
- 12.9.3 AbbVie Revenue in Extended-release Medication Business (2021-2026)
- 12.9.4 AbbVie Extended-release Medication Product Portfolio
- 12.9.5 AbbVie Recent Developments
- 12.10 AstraZeneca
- 12.10.1 AstraZeneca Company Information
- 12.10.2 AstraZeneca Business Overview
- 12.10.3 AstraZeneca Revenue in Extended-release Medication Business (2021-2026)
- 12.10.4 AstraZeneca Extended-release Medication Product Portfolio
- 12.10.5 AstraZeneca Recent Developments
- 12.11 Endo Pharmaceuticals
- 12.11.1 Endo Pharmaceuticals Company Information
- 12.11.2 Endo Pharmaceuticals Business Overview
- 12.11.3 Endo Pharmaceuticals Revenue in Extended-release Medication Business (2021-2026)
- 12.11.4 Endo Pharmaceuticals Extended-release Medication Product Portfolio
- 12.11.5 Endo Pharmaceuticals Recent Developments
- 12.12 Collegium Pharmaceutical, Inc
- 12.12.1 Collegium Pharmaceutical, Inc Company Information
- 12.12.2 Collegium Pharmaceutical, Inc Business Overview
- 12.12.3 Collegium Pharmaceutical, Inc Revenue in Extended-release Medication Business (2021-2026)
- 12.12.4 Collegium Pharmaceutical, Inc Extended-release Medication Product Portfolio
- 12.12.5 Collegium Pharmaceutical, Inc Recent Developments
- 12.13 China Res Double-Crane
- 12.13.1 China Res Double-Crane Company Information
- 12.13.2 China Res Double-Crane Business Overview
- 12.13.3 China Res Double-Crane Revenue in Extended-release Medication Business (2021-2026)
- 12.13.4 China Res Double-Crane Extended-release Medication Product Portfolio
- 12.13.5 China Res Double-Crane Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst